(24/7 MARKET NEWS) – Kala Pharmaceuticals, Inc. (NASDAQ: KALA) reported financial results, yesterday morning, for the third quarter and provided a corporate update, but is only now reacting to the highlights, which include planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022, with topline data expected in 1Q 2024 and its $52.4 million in cash is sufficient for funding operations into 2Q 2024.
Kala is trading at $6.50, up $1.28 (+24.52%), on over 50 thousand shares traded, which has already eclipsed yesterday’s volume.
Its 52-week range is $4.9197 to $114.00, with key inflection points being $6.55 and $6.99.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
